Collectively, these findings establish TM7SF2-mediated cholesterol metabolism as a druggable vulnerability in refractory lung cancer and underscore marine-derived bromotyrosine scaffolds as promising chemical platforms for overcoming kinase inhibitor resistance. The gene discussed is TM7SF2; the disease is lung cancer.